Oral Excipients

Introduction Capsule-based drug delivery systems have advanced considerably, enabling improved protection of active pharmaceutical ingredients (APIs) and controlled release along...

Abstract Reverse micelles (RM) have played a central role in biotechnology, yet their pharmaceutical use has been constrained by instability,...

Introduction Oral delivery of emerging drug modalities such as peptides, PROTACs, and siRNA is hindered by low intestinal permeability and...

Abstract During development of lipid-based formulations (LBFs) for poorly soluble drugs, formulations are often ranked according to in vitro API...

Introducing our new excipients To answer the rising need for oral solid dosage forms, Gattefossé innovates and creates new grades...

Abstract Tacrolimus is a potent calcineurin inhibitor suitable for the local treatment of oral mucosal immune-mediated diseases; however, no buccal...

WILMINGTON, Del., October, 2026 Ashland is spotlighting several new and expanded pharmaceutical solutions during CPHI Milan and at AAPS PharmSci...

Osteoarthritis (OA) is a prevalent chronic joint disease characterized by pain, swelling, and physical disability. Its management commonly involves anti-inflammatory...

DRUGCOAT® Polymers DRUGCOAT® polymer DRUGCOAT® has played a pivotal role in the evolution of the global pharmaceutical industry, setting new...

Abstract Lipid nanoparticles (LNPs) administered parenterally often show poor localization to multiple tissue types, including the pancreas and gastrointestinal (GI)...